 |
- Home
- Products
- Clinical Trials
- About QI
- Mission Statement
- News
- Publications
- Contact QI
- Resources
- Locating Clinical Trials
- National Cancer Institute
- University of South Alabama
- NCBI
- National Alliance of Breast Cancer
- National Breast Cancer Organization
- National Breast Cancer Coalition
- Young Survival Coalition
- The Mayo Clinic
- Cancer Center of John Hopkins
- Sloan Kettering Cancer Center
- Harvard Cancer Center
Member Sign In.
 |
 |
Quantum Immunologics is in the process of developing an immunologic treatment for breast cancer that may have positive effects on other types of cancer as well. Phase I and II clinical trials are currently under way in Tampa Florida. The current trial has a patient base of 27 women with stage IV breast cancer.
QI's Individualized ImmunotherapyTM is the result of years of research by staff at the University of South Alabama, College of Medicine and licensed by the South Alabama Medical Science Foundation. The technology centers on an immunogenic, cancer specific protein named OncoFetal Antigen/Immature Laminin Receptor Protein (OFA/iLRP). Several patents are involved in the process, with significant new patents having been filed as well.
Quantum Immunologics is a privately held company. Following all successful trials and approval by the FDA, the company plans to market the treatment, initially in the United States, for the treatment of breast cancer. Studies regarding its use in other types of cancer, as well as a new cancer screening tool are planned.
For additional information regarding QI's current clinical trial, please click here.
To view QI's full Company Profile, please click here